CALGARY, June 5, 2017 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announcethat a recently submitted paper titled: "Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)" was published in the Journal of Cardiovascular Translational
Apabetalone Published In Journal of Cardiovascular Translational Research
This publication discusses how through transcriptional regulation, apabetalone modulates pathways that underlie cardiovascular disease (CVD) including reverse cholesterol transport, vascular inflammation, coagulation, and complement a pathway which includes many CVD risk factors that are dysregulated. Using advanced technologies such as transcriptomics and proteomics the data clearly illustrated that complement is one of the pathways most downregulated by apabetalone in cells and in plasma from CVD patients previously treated with apabetalone. Plasma proteomics of CVD patients shows that apabetalone significantly decreases complement proteins and regulators indicating decreased activity of complement in patients. As complement components are linked to CVD and metabolic syndrome, including major acute cardiac events, modulating their levels and activity by apabetalone may alleviate risks associated with these diseases.
Commenting on the recent publication, Mr. Donald McCaffrey, President and Chief Executive Officer stated, "This is but one of several papers we will publish this year in the field of BET inhibition and epigenetics. I am extremely pleased that our science team continues to demonstrate leadership in the field of BET inhibition and the potential for apabetalone to reduce risks associated with CVD related diseases. Resverlogix, with its lead compound, apabetalone, was the first to utilize a BET inhibitor (BETi) in human clinical trials for treatment of CVD and other chronic diseases, which continues to provide us with a distinct competitive advantage in industry".
The publication may be obtained by clicking this LINK.
BIO International 2017 Presentation
Resverlogix also announces that Mr. Donald McCaffrey, President and Chief Executive Officer, is scheduled to present at BIO International 2017, in San Diego, CA, in which a corporate update will be provided.
Date: Monday, June 19, 2017Time: 4:15pm PDT
The presentation will be available on the Company website, on the Events/Webcasts page immediately prior to the scheduled presentation time.
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, dialysis, Alzheimer's disease, Fabry disease, other orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Apabetalone is currently in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL), and is expected to be initiated in a Phase 2a kidney dialysis trial designed to evaluate biomarker changes and safety parameters in up to 30 patients with end-stage renal disease treated with hemodialysis.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog
For further information please contact:
Investor RelationsEmail: email@example.comPhone: 403-254-9252Or visit our website: www.resverlogix.com
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the potential role of apabetalone in the treatment of cardiovascular disease, CVD, DM, chronic kidney disease, CKD, end-stage renal disease treated with hemodialysis, Alzheimer's disease, vascular calcification, and Orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Resverlogix Corp.
Subscribe to our Free Newsletters!
Nocturnal polyuria refers to increased urine output during night, without an associated increase in ...
Nootropics are drugs or substances which improve cognition that are being increasingly used ...
Pterygium or Surfer's eye is described as a proliferative disorder of the ocular surface possibly ...View All